Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Does aspirin use reduce cardiovascular risk in diabetes?

Nature Reviews Endocrinology volume 5, pages 188–190 (2009)Cite this article

The use of aspirin for the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus is controversial. According to the findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular events in this group of patients, unless they are aged 65 years and above.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).

    Article  CAS  Google Scholar 

  2. Patrono, C., Garcia Rodriguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373–2383 (2005).

    Article  CAS  PubMed  Google Scholar 

  3. Ogawa, H. et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300, 2134–2141 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Sacco, M. et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26, 3264–3272 (2003).

    Article  CAS  PubMed  Google Scholar 

  5. [No authors listed] Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS Investigators. JAMA 268, 1292–1300 (1992).

  6. Hansson, L. et al. Effects of intensive blood-pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study. Lancet 351, 1755–1762 (1998).

    Article  CAS  Google Scholar 

  7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).

    Article  PubMed Central  Google Scholar 

  8. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 30 (Suppl. 1), S4–S41 (2007).

  9. A Study of Cardiovascular Events in Diabetes. [http://www.ctsu.ox.ac.uk/ascend/about_pro.htm] (accessed February 9, 2009).

  10. De Berardis, G. et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8, 21–29 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 816, Charleston, SC 29425, USA colwelja@musc.edu

Authors and Affiliations

  1. Medical University of South Carolina, Charleston, SC, USA

    John A. Colwell

Authors
  1. John A. Colwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colwell, J. Does aspirin use reduce cardiovascular risk in diabetes?. Nat Rev Endocrinol 5, 188–190 (2009). https://doi.org/10.1038/nrendo.2009.44

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2009.44

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing